Vaxart Inc Stock Price, News & Analysis

Vaxart, Inc. (Nasdaq: VXRT) announced the appointment of Dr. David Wheadon to its Board of Directors, leveraging his extensive experience in global health policy and regulatory affairs. Dr. Wheadon, previously at AstraZeneca, aims to guide Vaxart as it advances its oral vaccine portfolio, including a COVID-19 candidate set for Phase 2 trials. Vaxart’s innovative tablet vaccines promise to simplify vaccination logistics, reducing the need for refrigeration and needle use. This strategic addition to the board is expected to enhance Vaxart's leadership and development capabilities.

Nearly 19 million Americans who currently refuse vaccines would consider vaccination if offered a pill option, according to a Vaxart commissioned poll. Conducted by Quadrant Strategies, the survey indicates that 70% of respondents prefer a pill over injection. The potential impact includes improving vaccination rates among underrepresented minority groups. Vaxart has completed Phase 1 of its oral COVID-19 vaccine, achieving necessary safety and immunogenicity endpoints. The findings emphasize the need for alternatives to needle injections to enhance public health efforts.

SOUTH SAN FRANCISCO, Calif., March 04, 2021 – Vaxart, a clinical-stage biotechnology company focused on oral recombinant vaccines, announced its participation in the H.C. Wainwright Global Life Sciences Conference, scheduled for March 9-10, 2021. The presentation will be available on-demand starting at 7 a.m. ET on March 9 through the conference portal and on Vaxart’s website afterward. Vaxart is developing several oral vaccines targeting coronavirus, Norovirus, seasonal influenza, respiratory syncytial virus (RSV), and human papillomavirus (HPV), aiming to revolutionize vaccine delivery and storage.

Vaxart, Inc. plans to advance its oral COVID-19 vaccine candidate, VXA-CoV2-1, to Phase 2 testing in Q2 2021. The company reported a cash balance of $126.9 million as of December 31, 2020, reflecting significant capital influx from various funding sources. The fourth-quarter revenue was $356,000, down from $3.9 million in 2019, primarily due to a drop in royalty revenue. The net loss for Q4 2020 was $13.9 million, with R&D expenses increasing to $8.6 million driven by COVID-19 vaccine developments. A strategic conference call is scheduled for March 2, 2021.

Vaxart, a clinical-stage biotechnology company, will host a conference call and business update on March 2, 2021, at 4:30 PM ET. The company specializes in developing oral recombinant vaccines that are tablet-administered rather than injected. Vaxart aims to create vaccines for various diseases, including coronavirus, Norovirus, and seasonal influenza, using a proprietary delivery platform that eliminates the need for refrigeration. This innovative approach also reduces the risk of needle-stick injuries.

Vaxart, Inc. (NASDAQ: VXRT) announced preliminary results from its Phase 1 study of the oral COVID-19 vaccine candidate, VXA-CoV2-1. The study met its primary endpoint of safety and secondary endpoint of immunogenicity, showing potent CD8⁺ T-cell responses. The vaccine demonstrated potential protection against new COVID-19 variants by including both Spike and N proteins. Results from 495 subjects indicated no severe adverse events, and mild gastrointestinal reactions were the most common. Vaxart plans to advance the vaccine into Phase II studies.

Vaxart (NASDAQ: VXRT) announced findings from a study published in the American Journal of Preventative Medicine, revealing economic advantages of a potential norovirus vaccine. A computational model indicated that a vaccine priced up to $1,300 could yield cost savings for children under 5, while one costing up to $100 could be cost-effective for older adults. The study highlights norovirus's impact on public health, projecting significant reductions in symptomatic cases through vaccination. Vaxart plans to initiate three clinical trials in 2021.

Vaxart, a clinical-stage biotechnology company, announced new pre-clinical data showing its oral COVID-19 vaccine significantly reduced lung inflammation in hamster models. Published in Nature Medicine, the study highlighted a substantial reduction in viral load and robust antibody responses. CEO Andrei Floroiu emphasized the vaccine's room-temperature stability, enhancing transport and storage. Phase I trial data is anticipated next week. The selected vaccine candidate also targets the nucleocapsid protein, potentially improving cross-protection.

Vaxart, Inc. (NASDAQ: VXRT) will host an investor panel on November 19, 2020, featuring key opinion leaders discussing their oral vaccine technology aimed at combating COVID-19 and Norovirus. The panel includes insights on immunity, disease prevention, and Vaxart's investigational vaccines. Management will update on their Phase 1 trial for Norovirus and provide preclinical data for their oral COVID-19 vaccine candidate, VXA-CoV2-1. The company emphasizes the potential advantages of oral vaccines over traditional injections, including ease of distribution and administration.